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The ﬁbrolamellar variant of hepatocellular carcinoma (FL-HCC) is a primary malignancy of the liver
classically identiﬁed in the non-cirrhotic liver. By virtue of the non-cirrhotic liver background, pa-
tients with FL-HCC are more likely to be selected for surgical resection as primary treatment than in
classic HCC. Synchronous and metachranous metastasis of FL-HCC can be treated with either
resection, chemotherapy, or both. We present here an adolescent who underwent resection of a large
FL-HCC following neo-adjuvant chemotherapy. The patient went on to receive surveillance and
resection of ﬁve serially identiﬁed metastasis. Despite repeated aggressive metastasectomy, we
observed survival in this case surpassing the median reported survival for adolescents with FL-HCC.
This case supports the hypothesis proposed previously that aggressive surgical resection, including
metastasectomy in the thoracic and abdominal cavity, should be offered to patients with this rare
tumor.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The ﬁbrolamellar variant of hepatocellular carcinoma (FL-HCC)
is a primary malignancy of the liver classically identiﬁed in the non-
cirrhotic liver. This may in part account for better prognosis in
FL-HCC patients compared to HCC patients. FL-HCC differ from
classic HCC in that they typically appear in non-cirrhotic liver,
present at a younger age, are often not associated with elevation in
AFP. Liver biopsy is more often required for the diagnosis of FL-HCC.
The management of this tumor is mirrored on established
practice for classic HCC. Aggressive surgical resection is more
feasible for patients with FL-HCC due to the tolerance for lower
post-resection future liver remnant in the typical non-cirrhotic
context, than in the class form of HCC presenting in a cirrhotic
background.
The two largest and most recent case series have deﬁned the
natural history of adolescents with FL-HCC treated primarily with
surgery [1,2]. The median overall survival is 52e57 months, and
5-year overall survival is 42.6%. Factors associated with favorable
outcome are early PRETEXT or AJCC stage, negative regional lymphInc. This is an open access article unode involvement, white race, female gender, and complete sur-
gical resection.
While resection for metastatic deposits of FL-HCC has been
advocated, there is paucity in case series or reports of any more
than two metastasectomies in the same patient. Presented here is a
case of a locally advanced FL-HCC in an adolescent, initially treated
with neo-adjuvant chemotherapy followed by resection of the liver
tumor. The patient subsequently developed serially ﬁve meta-
chronous metastases over the course of ﬁve years that were each
treated with resection at the time of identiﬁcation.
1. Case
A 15-year-old boy was referred to the pediatric general surgeon
with an abdominal mass and ultrasound showing a heterogenous
mass arising from the liver. He was otherwise healthy. Laboratory
studies revealed a normal total bilirubin (6 umol/L) and alkaline
phosphatase (184 U/L), but elevated ALT (88 U/L) and AFP 93 ug/L.
Other tumor markers were within normal limits CEA (<1 ug/L) and
HCG <5 U/L.
Further evaluation with triphasic CT scan (Fig. 1) demon-
strated a large heterogeic hypervascular mass in the left lobe ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Selected images from CT scan of the abdomen showing heterogeneous lesion of the left liver in axial (A) and coronal (B and C) section.
Fig. 2. Metastatic deposit in the cardiophrenic angle identiﬁed by arrow. Proximity to
pericardium, phrenic nerve, and diaphragm illustrated.
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lesion contained course internal calciﬁcations with central
necrosis. Satelite lesion in segment 4 and enlarged hepatic hilum
node. Core needle biopsy of the mass was diagnostic for FL-HCC.
After multi-disciplinary review, a three-month course of
doxorubicin, cisplatin, and sorafenib was initiated; however, post-
treatment imaging failed to show tumor response. Unfortunately,
the patient exhibited sorafenib related skin toxicity. The patient
went on to receive angiographic embolization of the tumor using
Therosphere (Yttrium-90 glass particles) and accessory LHA bland
embolization. Regression in tumor volume and AFP was noted at
11 months after initial diagnosis. This was followed by surgical
resection including left hepatectomy (11.5  8  6 cm tumor), and
resection of the celiac, gastro-hepatic, and para-aortic lymph
nodes which were all identiﬁed to contain metastatic HCC.
Following an uncomplicated recovery from surgery, serum AFP
level was normal.
At 18 months there was an increase in the serum AFP and amass
was identiﬁed at the cardiophrenic angle on axial imaging. This was
resected via left thoracotomy, and histopathology demonstrated a
metastatic deposit of HCC (Fig. 2).
At 27 months following initial presentation, a mass was identi-
ﬁed between the tail of pancreas, left adrenal gland and spleen.
Resection of this metastasis was achieved with en bloc distal
pancreatectomy and splenectomy (Fig. 3).
At 30 months, a recurrence was identiﬁed in the hepato-
duodenal ligament, and resection preserving the portal vein, he-
patic artery, and bile duct was achieved.
The patient was surveyed for an additional year and a half during
which time there was no recurrence; however, at four years
following initial presentation left pulmonary hilum was identiﬁed.
Resection was achieved through a repeated left thoracotomy. The
mass was identiﬁed to be abutting but not invading the left pul-
monary artery, left main stem bronchus, and aortic arch (Fig. 4).
One year later, an anterior mediastinal mass was identiﬁed. This
was surgically resected via sternotomy, and identiﬁed to be
metastasis within the thymus (Fig. 5).
At 5-years from the time of initial presentation; the patient re-
ported symptoms of abdominal pain. He was found to have anunresectable retroperitoneal mass with association of the portal-
splenic vein conﬂuence in the head of the pancreas.2. Discussion
FL-HCC was at ﬁrst thought to be relatively indolent compared
to classic HCC; however superior prognosis of FL-HCC likely sec-
ondary to resectability afforded by the non-cirrhotic patient rather
than a function of tumor biology [3]. Both of the largest and most
recent case series in FL-HCC support an approach including surgical
resection including involved lymph nodes and metastasis as the
ﬁrst-line treatment of FL-HCC, reporting associated with better
prognosis.
Peritoneal, lymphatic, pulmonary [4], and even pancreatic
metastasectomy [5] have been described for FL-HCC; however, only
one case report has documented a second metastasectomy on a
single patient [6]. Kow et al. in their series have reported the overall
survival of patients with metastatic FL-HCC undergoing peritoneal
Fig. 3. Metastatic FL-HCC identiﬁed in the left upper quadrant of the abdomen identiﬁed on CT scan (A) and Gallium Scan (B). Surgical photos demonstrate tumor in situ (C) and
specimen (D) showing proximity to spleen and tail of pancreas.
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stasectomy to be 92%, 55%, and 55% at 1-year, 3-year, and 5-year,
respectively. The median time-to-recurrence was 18 months
following peritoneal and 12 moths following pulmonary meta-
stasectomy [4].Fig. 4. Metastatic FL-HCC to the left thoracic cavity with surgical photographs showing tum
pulmonary artery (PA), left main stem bronchus (LMSB), and thoracic aorta.Here, we describe over 5-year survival after initial presentation
of a borderline resectable FL-HCC treated with neo-adjuvant down-
staging to allow for resection of the primary tumor, followed by
serial imaging and early metastasectomy for a total of 6 operative
resections.or (A) and surgical ﬁeld after resection (B) illustrating abutment of tumor on the left
Fig. 5. Surgical photograph of metastatic deposit of FL-HCC identiﬁed in the medias-
tinum accessed via sternotomy.
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surpassing the median reported survival for adolescents with FL-
HCC [1,2]. This case supports the hypothesis proposed previously
that aggressive surgical resection, including metastasectomy in the
thoracic and abdominal cavity, should be offered to patients with
this rare tumor.References
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